Description: Xeris Pharmaceuticals Inc is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations.
Home Page: www.xerispharma.com
XERS Technical Analysis
180 North LaSalle Street
Chicago,
IL
60601
United States
Phone:
844 445 5704
Officers
| Name | Title |
|---|---|
| Mr. Paul R. Edick | Chairman & CEO |
| Mr. John P. Shannon | Pres & COO |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corp. Sec. |
| Dr. Steven J. Prestrelski MBA, Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. Steven M. Pieper | Chief Financial Officer |
| Ms. Allison Wey | Sr. VP of Investor Relations & Corp. Communications |
| Dr. Kenneth E. Johnson Pharm. D., Pharm.D. | Sr. VP of Global Devel. & Medical Affairs |
| Mr. Kevin McCulloch | Chief Commercial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.4095 |
| Price-to-Sales TTM: | 1.8493 |
| IPO Date: | 2018-06-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 294 |